The company received net proceeds of approximately $1.9 million in the offering and converted an additional $1.9 million in previously convertible debentures as part of the offering.
Three million patients are treated for restricted coronary blood flow every year.
To date, most CTC capture and detection technologies have not been able to recognize the cytokeratin negative (CK‐) CTCs. Biocept’s Cell Enrichment and Extraction (CEETM) platform allows for the capture of these CK- cells as well as CK+ CTC phenotypes
The MEMS technology, which was originally developed as a movement system for nano-robots is also used in devices such as the iPhone and Nintendo Wii.
“I am very pleased with the performance of this new device to identify high risk patients so they can be treated appropriately with progesterone therapy to prevent preterm delivery.”
A recent product of note is the BlackLight® Sepsis Kit, which is currently under clinical evaluation. The sepsis detection kit has been extensively tested on real hospital samples, which have led to recognition of both common and rarer pathogens.
AccuGenomics is currently recruiting lung cancer patients for clinical trials of their Lung Cancer Risk Test
Congestive heart failure affects as many as 5 million Americans and with an aging population, more than half a million patients are diagnosed with the condition each year.
CorInnova is currently trialing a cardiac compression device known as CorAmend that can be implanted and explanted without ever contacting the patient’s blood
The Cyclone System allows a surgeon to eliminate the aortic side-biting clamp traditionally used in coronary artery bypass grafting (CABG).
Copyright © 2024 | WordPress Theme by MH Themes